Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

261 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
Becker REN, Meyer AR, Brant A, Reese AC, Biles MJ, Harris KT, Netto G, Matoso A, Hoffman-Censits J, Hahn NM, Choi W, McConkey D, Pierorazio PM, Johnson MH, Schoenberg MP, Kates MR, Baras A, Bivalacqua TJ. Becker REN, et al. Among authors: baras a. Eur Urol. 2021 Mar;79(3):364-371. doi: 10.1016/j.eururo.2020.07.016. Epub 2020 Aug 17. Eur Urol. 2021. PMID: 32814637
Involvement of epigenetics and EMT-related miRNA in arsenic-induced neoplastic transformation and their potential clinical use.
Michailidi C, Hayashi M, Datta S, Sen T, Zenner K, Oladeru O, Brait M, Izumchenko E, Baras A, VandenBussche C, Argos M, Bivalacqua TJ, Ahsan H, Hahn NM, Netto GJ, Sidransky D, Hoque MO. Michailidi C, et al. Among authors: baras a. Cancer Prev Res (Phila). 2015 Mar;8(3):208-21. doi: 10.1158/1940-6207.CAPR-14-0251. Epub 2015 Jan 13. Cancer Prev Res (Phila). 2015. PMID: 25586904 Free PMC article.
Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes.
Gandhi NM, Baras A, Munari E, Faraj S, Reis LO, Liu JJ, Kates M, Hoque MO, Berman D, Hahn NM, Eisenberger M, Netto GJ, Schoenberg MP, Bivalacqua TJ. Gandhi NM, et al. Among authors: baras a. Urol Oncol. 2015 May;33(5):204.e1-7. doi: 10.1016/j.urolonc.2015.02.011. Epub 2015 Mar 23. Urol Oncol. 2015. PMID: 25814145 Free PMC article.
Correction: Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma.
Baras AS, Gandhi N, Munari E, Faraj S, Shultz L, Marchionni L, Schoenberg M, Hahn N, Hoque MO, Berman D, Bivalacqua TJ, Netto G. Baras AS, et al. PLoS One. 2015 Nov 24;10(11):e0143990. doi: 10.1371/journal.pone.0143990. eCollection 2015. PLoS One. 2015. PMID: 26599435 Free PMC article. No abstract available.
Accuracy of urethral frozen section during radical cystectomy for bladder cancer.
Kates M, Ball MW, Chappidi MR, Baras AS, Gordetsky J, Sopko NA, Brant A, Pierorazio PM, Epstein JI, Schoenberg MP, Bivalacqua TJ. Kates M, et al. Among authors: baras as. Urol Oncol. 2016 Dec;34(12):532.e1-532.e6. doi: 10.1016/j.urolonc.2016.06.014. Epub 2016 Jul 16. Urol Oncol. 2016. PMID: 27432433
The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder.
Baras AS, Drake C, Liu JJ, Gandhi N, Kates M, Hoque MO, Meeker A, Hahn N, Taube JM, Schoenberg MP, Netto G, Bivalacqua TJ. Baras AS, et al. Oncoimmunology. 2016 Feb 18;5(5):e1134412. doi: 10.1080/2162402X.2015.1134412. eCollection 2016 May. Oncoimmunology. 2016. PMID: 27467953 Free PMC article.
261 results